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ABSTRACT 
Cardiovascular disease (CVD) is the leading cause of death in minority populations in the 
United States, yet minority patients tend to be under-represented in cardiovascular disease 
research. The under-representation of minorities in clinical research raises two major issues. 
First, low minority participation levels mean that study findings are not applicable or able to be 
generalized to minority patients. Second, social justice and research ethics require that the 
benefits and burdens of clinical research be shared equally among the potential beneficiaries of 
the research; by not participating in research, minority patients may not benefit from access to 
new treatments or prevention programs. 
Many studies have identified barriers to minority patient participation in clinical research, 
including distrust of medical researchers and fear of harm; lack of knowledge; lack of 
transportation; interference with work or family responsibilities; burden of participation; 
financial costs; language or literacy issues; and restrictive study designs. Much has been written 
about strategies for overcoming these barriers and increasing minority patient participation in 
cancer and HIV I AIDS research. This paper examines potential strategies for increasing minority 
patient participation in cardiovascular disease research. Specifically, this paper addresses five 
questions: What strategies have been documented for increasing the participation of minority 
patients in cardiovascular disease research in the United States? What strategies have been 
documented for increasing the participation of minority patients in research in other disease areas 
or in clinical research generally (e.g., not in a specific disease area)? Are these strategies 
adaptable for cardiovascular disease? Has the effectiveness (and possibly relevant effectiveness) 
of the strategies been assessed? Are there opportunities for collaboration between the clinical 
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research and public health sectors to implement new strategies and/or to implement existing 
strategies more efficiently? 
The primary source of information for this paper was a literature review. The literature 
review identified few strategies specifically designed to increase minority participation in CVD 
research. Strategies designed for other disease areas or for clinical research generally may be 
adapted for CVD research, but assessments of the effectiveness of these strategies are necessary 
before they are widely implemented. Few assessments of strategy effectiveness are available for 
any disease area. 
New research should be conducted to develop and test effective strategies for CVD 
research. New strategies and approaches are needed at both the individual study level and the 
broader systems level. Addressing the issue from a public health leadership standpoint may be 
particularly useful for developing new systems level strategies. Researchers should also 
investigate the potential for partnerships with public health organizations that are already 
investing in education, prevention, and treatment campaigns for CVD. 
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INTRODUCTION 
Cardiovascular disease is the leading cause of death in minority populations in the United 
States, yet minority patients tend to be under-represented in cardiovascular disease research. 
This has important implications for prevention and treatment of CVD in these populations, as 
there may be biological differences in risk factors and response to treatment. Much has been 
written about strategies for increasing minority patient participation in cancer and HIV I AIDS 
research. This paper examines potential strategies for increasing minority patient participation in 
cardiovascular disease research. The paper includes a summary of the issue, a description of the 
methods and findings of a literature review on this topic, and a discussion of future research and 
policy needs. 
PREVALENCE OF CARDIOVASCULAR DISEASE (CVD) 
Cardiovascular disease (CVD) refers to a broad set of clinical conditions that affect the 
heart and circulatory system. The four most common forms of CVD are coronary heart disease, 
stroke, hypertension, and heart failure. 1 As of 2006, more than 80 million Americans (nearly one 
third of the population) had a history of some form ofCVD.2 CVD of all forms is the leading 
cause of death in the United States, accounting for nearly 35 percent of all deaths in 2006.3 CVD 
also results in significant health care expenditures in the United States, with estimated direct and 
indirect costs for 2010 of$503.2 billion.4 
CVD is particularly problematic in minority populations in the United States. For the 
purposes of clinical research, the National Institutes of Health (NIH) uses race and ethnicity 
classifications. The races are American Indian or Alaska Native, Asian, Black or African 
American, Native Hawaiian or Other Pacific Islander, and White. The ethnicities are Hispanic or 
Latino and not Hispanic or Latino. Non-Hispanic Whites are considered the majority group in 
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the United States; the remaining races and ethnicity are considered minority populations. 5 
African American men face a 30 percent higher risk of dying from CVD than non-Hispanic 
white men. African Americans are also more likely to have hypertension, a major risk factor for 
CVD, than non-Hispanic whites (32 percent compared to 22.5 percent). American Indians and 
Alaska Natives have the highest percentage of premature deaths from CVD, while whites have 
the lowest percentage.6 Hispanic/Latinos are more likely to be overweight or obese, a major risk 
factors for CVD, than non-Hispanic whites; over 70 percent of Hispanic/Latina adults are 
overweight or obese? Diabetes is another major risk factor for CVD that disproportionately 
affects minority populations. Over 10 percent of African Americans and Hispanic/Latinos and 
over 9 percent of American Indians have diabetes, compared with only 6.2 percent of non-
Hispanic whites. 8 
CLINICAL RESEARCH IN CVD 
Due to its prevalence and high mortality rates, CVD is the focus of large amounts of 
clinical research on its risk factors, prevention, and treatment. A simple search of 
ClinicalTrials.gov identified over 11,000 research studies in the area of CVD.9 The NIH spends 
approximately 7 percent of its budget on research related to cardiovascular disease. 10 The 
federal government also supports CVD research through agencies such as the Centers for 
Disease Control and Prevention and the Agency for Healthcare Research and Quality. In the 
private sector, non-profit organizations, such as the American Heart Association, and academic 
centers fund large amounts of research. Pharmaceutical and device manufacturers are also very 
active in CVD research. 
MINORITY PATIENT PARTICIPATION IN CVD RESEARCH 
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CVD is a significant health problem in minority populations. Concurrently, a large 
amount of CVD research is being conducted. Despite these two facts, minority groups tend to be 
under-represented in CVD research. A systematic review on this topic examined whether major 
cardiovascular cohort studies inN orth America and Europe included or excluded ethnic minority 
populations. Of the 72 studies included in the review, only 1 0 were designed to compare white 
and minority populations, and only five studies specifically focused on one minority group. All 
15 of these studies were conducted in the United States. The authors concluded that there is a 
lack of data from CVD cohort studies on minority patient populations. 11 
A second systematic review assessed participation in CVD research. In this case, the 
authors examined the literature to assess the participation of minority groups in clinical trials of 
antihypertensive drug therapy and to identify any differences in efficacy for these therapies. 
Twenty-eight studies were included in the review. Of these, 12 did not report any information on 
participants' tace/ethnicity, and eight studies reported information on participants' race/ethnicity, 
but did not examine outcomes by race/ethnicity. Only eight studies reported on outcomes by 
. . b 12 mmonty su group. 
In fact, minority populations are under-represented in clinical research generally. A 2007 
article in the Journal of Clinical Endocrinology & Metabolism summarized the problem, stating, 
"The underrepresentation of minorities occurs in all types of clinical research and all therapeutic 
areas, including those diseases that predominantly affect ethnic minorities."13(P3) Low 
participation rates have been particularly well documented in cancer research. For example, a 
review of cancer drugs approved by the U.S. Food and Drug Administration between 1995 and 
1999 found that minority groups (collectively African Americans, Asian/Pacific Islanders, 
Hispanics/Latinos, and Native Americans) represented less than 10 percent of trial participants. 
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The National Cancer Institute (NCI), which sponsors a large volume of cancer research, has also 
reported low minority participation rates. Between 1998 and 2001, NCI reported an increase of 
22 percent in trial enrollment; however, during the same time frame, the number of minority 
patients enrolling in trials remained the same. The result was a decrease in the overall 
percentage of minorities in enrolling in trials. 14 Graph 1 below surnrnarizes the minority patient 
participation issue in cancer research; the graph depicts enrollment in cancer clinical trials 
between January 2003 and June 2005. 
Graph 1: Cancer Clinical Trials: Enrollment by Race and Ethnicity15 
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Source: National Cancer Institute. Data from January 2003 to June 2005. 
BARRIERS TO MINORITY PATIENT PARTICIPATION IN CVD RESEARCH 
In response to the well-documented low rates of minority patient participation in clinical 
research, several studies have attempted to identifY the barriers to minority participation. Only 
one of these studies examined the question specifically for CVD. In that study, the researchers 
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used a survey to assess willingness to participate in a hypothetical cardiovascular drug trial 
among African Americans. The authors found that African Americans were less likely to 
express a willingness to participate than whites (27 percent vs. 39 percent). African American 
participants also expressed more concern about potential harm from participating in the trial and 
more distrust of the medical researchers than white participants. The authors concluded that 
these factors are significant barriers to recruiting African Americans to participate in clinical 
research. 16 
Several other studies and reports have described general barriers to participation. 
Socioeconomic factors influence a number of the obstacles to participation in clinical research. 
Financial incentives to participate may offset costs incurred from participation or compensate 
patients for time spent on study-related activities. However, it considered unethical to use 
financial compensation to incentivize participation in clinical research. In 2002, the NIH 
published an "Outreach Notebook For the Inclusion, Recruitment and Retention of Women and 
Minority Subjects in Clinical Research" as part of its efforts to increase the participation of 
women and minorities in clinical trials. The guide discusses the following six major barriers to 
clinical trial participation: distrust of medical researchers and fear of harm; lack of knowledge; 
lack of transportation; interference with work or family responsibilities; burden of participation; 
and financial costs. 17 These barriers are described below. 
Distrust of Medical Researchers and Fear of Harm 
Distrust of medical researchers and fear of harm from participating in clinical studies are 
often linked to historical events, such as the Nuremberg trial in 1949 and the Tuskegee syphilis 
study. At the Nuremberg trial, Nazi scientists were prosecuted for conducting unethical and 
inhumane experiments on human subjects.17 The Tuskegee syphilis study is an infamous 
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example of unethical treatment of research subjects. In this study, run by an agency of the U.S. 
govermnent, African American males with syphilis were denied treatment for their condition. 
Fears of research participant abuse led to efforts, such as the Declaration of Helsinki and the 
Good Clinical Practice Guidelines, to prevent such unethical behavior. 18•19 These guidelines for 
ethical research practices have been widely adopted by researchers, and many regulatory or 
funding agencies also require compliance with all or part of the guidelines. 
Despite these efforts to prevent abuse, mistrust of research lingers, particularly among 
minority groups. A 2002 study documented the strong belief among minority patients that 
participation in clinical research may harm one's health.20 In 2005, an Evidence Report from the 
Agency for Healthcare Research and Quality also documented distrust of medical researchers as 
a major barrier to minority patient participation in clinical trials.21 Several other studies have 
also examined barriers to participation among minority patients in relation to clinical research 
generally and found distrust of medical researchers to be a significant issue. 22•23•24•25•26•27•28 
Distrust of researchers may also be affected by stories of questionable research projects 
that are widely reported in the media. For example, in 2000, the Washington Post published an 
investigative series revealing research misconduct by Pfizer, a major American pharmaceutical 
company. The articles described a study that Pfizer conducted in Nigeria in 1996 to test a 
vaccine in children. Pfizer did not obtain informed consent before enrolling and treating the 
children, and the study used a falsified ethics approval letter. Eleven children died during the 
study, and many others were injured. In 2001, several of the Nigerian families involved in the 
study sued Pfizer, alleging that the company did not explain that the drug was experimental, 
offer other treatment choices, or obtain proper consent. Pfizer disputed the claims, but agreed to 
a $75 million settlement in 2009 after the Nigerian govermnent filed criminal charges against 
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Pfizer staff. 29 Another example, from 1999, involves a gene therapy trial at the University of 
Pennsylvania, where an 18-year old participant died from an adverse reaction to an experimental 
treatment. Investigations into the patient's death revealed that researchers had not disclosed all 
of the risks of participating in the study and that the lead researcher had a significant financial 
stake in the outcome of the study. The U.S. Food and Drug Administration (FDA) sanctioned 
the researchers, and the patient's family sued the researchers and the university, leading to an 
out-of-court settlement.30.3 1 Both of these incidents, as well as other examples of research 
misconduct, have received significant media coverage in the United States. Stories such as this 
are likely to increase patients' distrust of medical research. 
Lack of Knowledge 
Minority patients may not participate in clinical research because they are not aware of 
opportunities. In 2003, a national survey of cancer patients found that 85 percent of patients 
were not aware of clinical trials as a treatment option for their condition. 32 Physicians are often 
responsible for informing patients of clinical trials opportunities. If physicians, particularly 
primary care physicians, are not informed of research opportunities, patients are unlikely to learn 
of these opportunities. In some cases, physicians may not be aware of research opportunities. 
Minority patients are also more likely to see minority physicians, who in turn are less likely to 
participate in clinical research. 33 In a 2006 study, researchers reviewed the enrollment records 
for several health research studies and concluded that minority patients were less likely to be 
asked to participate in the study, compared to non-Hispanic whites.34 Even when physicians 
discuss clinical research opportunities with patients, patients may lack knowledge of clinical 
research protections and the informed consent process. The NIH guide notes that "some would-
be research participants believe that the informed consent document protects the research 
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institution and its staff while abridging the rights of the individual research participant. "35(ps?) 
Another possibility for lack of knowledge of clinical research among minority patients may be 
systematic differences in how these patients access care. For example, these patients may be 
more likely to receive treatment at urgent care clinics or emergency rooms, rather than in office 
visit settings. This type of difference could have a significant impact on minority patients' 
access to research opportunities. This issue was not discussed as a potential barrier to research 
participation in the literature reviewed for this paper, but it warrants further study. 
Lack of Transportation 
Many clinical research studies are conducted at specialized clinics or at academic 
teaching hospitals. These locations are not readily accessible to all potential research 
participants. 36 For some potential participants, lack oftransportation may pose a significant 
barrier to participation. This is a particular issue in rural areas and in underserved areas. In rural 
areas, the research site may be located a significant geographic distance from patient homes. For 
other patients, research sites may be located within the same general geographic area, but may be 
difficult to access for patients who do not own a car or do not drive. Research sites may be 
accessible by public transportation in some cases, but patients may find it too inconvenient or 
· I h · n expensive to trave to t e s1te. 
Inference with Work or Family Responsibilities 
Participation in clinical research may require a significant time commitment from 
patients to attend additional doctor appointments, undergo laboratory tests, or complete study 
diaries or surveys. Some patients may find these activities too difficult to fit into busy or 
unpredictable work schedules; others may be overwhelmed with caring for immediate and 
extended family members. Some patients may not be able to take time off from work to attend 
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additional doctor appointrnents?8 These barriers may be particularly significant for conditions 
that are not life-threatening and preventive studies. 39 
Burden of Participation 
Participation in clinical research may become more burdensome as researchers attempt to 
assess additional outcomes, such as genetic links to a disease or patient's perceptions of quality 
oflife. Significant burden, either in terms of time or in terms of the types of procedures 
required, may reduce patients' willingness to participate in clinical research.40 This barrier exists 
for all potential research participants -minority and otherwise. 
Financial Costs 
Some patients with limited financial resources may participate in a trial to gain access to 
a new and expensive medication. However, other patients with limited financial resources may 
be less likely to participate in clinical research due to worries about the financial cost of 
participating. This may be particularly true for studies of risk factors or preventive measures that 
do not involve new medications. Patients with limited financial resources may not be able to 
afford to take time off from work, or they may worry about incurring additional expenses, such 
as insurance co-pays, childcare costs, or transportation expenses.41 
Patients with limited financial resources and no insurance coverage may be even more 
hesitant to participate due to financial concerns. Clinical trial sponsors typically rely on insurers 
to cover the costs of the patient's usual care, such as office visits, laboratory tests, and surgical 
procedures. The trial sponsors usually only pay for additional procedures or tests that are done 
solely for research purposes. Patients without insurance may be hesitant to take part in a study 
that will require a certain number of office visits or laboratory tests, for which they will have to 
pay out-of-pocket. In a 2002 review of cancer treatment trials sponsored by the NCI, uninsured 
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patients represented only 5.4 percent of participants. The authors concluded that uninsured 
patients diagnosed with cancer tend to have more advanced disease, which may make them 
ineligible for some trials; in addition, these patients may be less likely to see cancer specialists 
who are involved in clinical trials. 42 Lack of insurance coverage may be an important barrier for 
minority patients, as these patients are less likely to be insured than other patients. In 2008, 19.1 
percent of African Americans, 17.6 percent of Asians, 31.7 percent of American Indians or 
·Alaska Natives, and 18.5 percent of Native Hawaiians and Other Pacific Islanders were 
uninsured. Among Hispanic or Latinos, 30.7 percent were uninsured. In comparison, only 10.8 
percent of non-Hispanic whites were uninsured.43 
Other Barriers 
In addition to the barriers identified by the NIH, other groups have identified language 
and literacy as major barriers specifically for minority groups in the United States. For example, 
many studies in the United States require patients to be proficient in English; this may be a major 
barrier for Hispanic/Latina and Asian patients. 44 Even patients who are proficient in English 
may not be able to read and understand complex documents, such as informed consent forms and 
other materials related to the clinical study. Patients may decline to participate in the study due 
to lack of understanding of the research study procedures and goals. 45 
Study design is another significant barrier, particularly among minority patients. 
Randomized clinical trials generally have strict inclusion and exclusion criteria.46 The goal of 
these criteria is to make the patients within the trial as similar as possible, to minimize the 
potential for other factors (e.g., other medications, other conditions) to influence the study 
results. However, the strict criteria can make many patients ineligible for the study; this is a 
important issue, since minority patient populations have high rates of certain co-morbidities (e.g., 
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hypertension). For example, in one study, researchers examined barriers to participation in 
cancer clinical trials at Howard University Cancer Center. The authors found that, as a result of 
strict inclusion/exclusion criteria, only 8.3 percent of African American cancer patients were 
eligible for clinical trial participation.47 Another study also documented study design factors as a 
barrier to minority patient enrollment in cancer clinical trials.48 
Lastly, some studies have suggested that the low number of minority physicians may be 
related to low participation rates among minority patients. In 2001, the American Medical 
Association reported that only 2. 7 percent of internal medicine physicians were African 
American, and only 3.3 percent were Hispanic. The percentages were similar for cardiologists. 
Two percent of cardiologists were African American, 3.8 percent were Hispanic, and 12.7 
percent were Asian.49 In 2007, a report from The Endocrine Society noted that African 
Americans, Hispanics/Latinos, and Native Americans, taken together, make up only 6.4 percent 
of physicians graduating from medical schools. The report acknowledges that there is a lack of 
data on the participation of minority physicians in clinical research. 50 
Other studies have found that minority patients are more willing to participate in research 
when invited by their own physician. Since minority patients tend to choose minority 
physicians, the authors of these studies conclude that increasing minority physician participation 
in research may increase minority patient participation in clinical studies. 51• 52 One study in 
particular found that distrust of medical researchers was less of a factor in minority patient 
participation than the lack of invitations to participate from their own physicians. 
SIGNIFICANCE OF LOW MINORITY PATIENT PARTICIPATION RATES 
As established above, minority patient populations are under-represented in clinical 
research, including in CVD research. Before examining specific strategies for increasing 
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minority patient participation in clinical research, the rationale for increasing participation must 
be examined. The major reasons for increasing participation fall into two categories: enhancing 
the applicability of study results, and improving access to research program and benefits. 
APPLICABILITY OF STUDY RESULTS 
The goal of clinical research, generally, is to examine the effects of an intervention 
among patients who are similar to the patients who will ultimately use the intervention. For 
example, a new medication for hypertension would, ideally, be tested in a population that is 
representative of the general population of people with hypertension, in terms of age, gender, 
race, co-morbidities, and use of other medications. The purpose of using a representative patient 
population in clinical research is to allow the study results to be generalized from the small 
patient population in the trial to the much larger patient population in the general public. 
However, the ability to generalize the study results is limited when minority patient 
populations are under-represented in the studies. Several studies that have included minority 
patients have found differences in outcomes based on race/ethnicity. One systematic review 
identified multiple studies where differences in efficacy among minority subgroups were 
reported. For example, the ALLHAT study found a greater beneficial effect for blacks taking a 
diuretic therapy than for non-blacks. Another study, the LIFE trial, reported worse outcomes 
among blacks using angiotensin-receptor blockers than among non-blacks. Two studies reported 
similar outcomes for Asians and non-Asians. Notably, no studies examined outcomes 
specifically for Native Americans. 53 
Other studies have identified differences in disease-specific risk factors among minority 
groups. For example, a 1998 study examined CVD risk factors among minority women and 
found that CVD risk factors are higher among minority women and among those of lower 
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socioeconomic status in the United States. Minority women were also more likely to be of lower 
socioeconomic status. The authors expected to find that socioeconomic status would 
substantially explain the higher rates of CVD risk factors among minority women, but the study 
data did not confirm the authors' hypothesis. Instead, the authors concluded that both race and 
socioeconomic status have independent associations with CVD risk factors, including systolic 
blood pressure and body mass index. 54 This finding is particularly important, given that risk 
prediction models for CVD have largely been developed using data from non-Hispanic white 
populations. 55 The problem of distinguishing the effects of socioeconomic status and race on 
treatment response and risk factors also exists in cancer. One study noted that, without increased 
participation of minorities in cancer research, drawing out these distinctions will be impossible. 56 
Some researchers have suggested that differences in outcomes and risk factors may be 
related to biological differences between racial/ethnic groups. Studies have found differences 
among racial/ethnic groups in the pharmacokinetics of some drugs and in the biologic course of 
some diseases. These differences may alter the effectiveness of some medications. 57•58•59 The 
most well known of these examples is the drug BiDil® (isosorbide dinitrate/hydralazine), which 
was approved by the FDA specifically for the treatment of heart failure in African Americans. 
The initial trial for the drug emolled men of various races, but the results were not statistically 
significant. Further analyses of the data showed that results were statistically significant among 
African American men. Researchers conducted a new placebo-controlled trial, emolling only 
self-identified African American men and women. The results of the second trial were 
statistically significant and were used to obtain FDA approval of the drug in 2005 60 The drug is 
not indicated for use in non-African American patients. 61 
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The potential racial and ethnic variations in the biologic course of disease and in the 
response to medications heighten the need for increased representation of minority groups in 
clinical research. Without increased representation, it will be difficult, if not impossible, to 
generalize study findings to minority groups. 
EQUAL ACCESS TO RESEARCH AND RESEARCH PROGRAM BENEFITS 
The second major reason for increasing minority patient participation in clinical research 
concerns social justice and ethics. As an issue of social justice, medical interventions must be 
tested in the populations that will ultimately use them. Findings from research studies are most 
likely to be useful to patients who are similar to the study participants. 62 Therefore, medical 
research, much of which is supported by public funding, must provide information on risk factors 
and prevention strategies that is useful to all racial and ethnic groups in the United States, not 
just the majority group.63 Increasing minority participation in research may also help address 
another major social justice issue - health care disparities in the United States. 64 As an issue of 
ethics, balancing the burden and benefits of research across all patient groups is critical; the 
majority group should not bear the entire burden of participating in research, nor reap all of the 
benefits of participation. 65 
Related to the ethics argument is the concept of equal access to research program 
benefits. As noted in a General Accounting Office report to Congress, clinical trials can be 
"especially important for patients with serious or life-threatening conditions that have limited 
treatment options. For those patients, participation in a clinical trial ... may offer the best chance 
of finding an effective treatment. "66(pl) In addition to potentially effective treatments, research 
programs may offer patients other benefits, such as access to new screening tools for some 
diseases or opportunities to participate in structured risk reduction programs (e.g., smoking 
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cessation or weight loss intervention studies). These programs could have a beneficial impact on 
the patient's health. 
EFFORTS TO INCREASE MINORITY PATIENT PARTICIPATION IN RESEARCH 
The problem of under-representation of minority groups in clinical research has received 
significant attention in recent years. Most notably, Congress acted in 1993 to increase minority 
patient participation in NIH-funded research. In response to the passage of the NIH 
Revitalization Act of 1993, the NIH revised its policies to require that women and minorities be 
included in all of its clinical research studies. The new policies require Phase III trial to include 
women and minorities in sufficient numbers to permit analyses of differences in treatment effect. 
The law specifically states that cost is not a valid reason to exclude minority patients. The law 
also required the NIH to develop programs and support for outreach efforts to recruit women and 
minority patients into clinical research programs. All studies that the NIH considers for funding 
must include specific plans for recruiting and retaining women and minority groups. 67 
The NIH also promotes increased minority patient participation in cancer research 
through the NCI's Community Clinical Oncology Program. This program connects community 
physicians with academic research centers to facilitate participation in cancer prevention and 
treatment research. Community hospitals and physicians organize themselves into groups that 
enter into cooperative agreements to participate in cancer clinical trials. Research centers who 
are conducting the studies then have direct access to community physicians who are interested in 
research opportunities. The program also includes minority-based groups, defined as groups 
with 40 percent or more of new patients coming from minority populations. Minority-based 
groups provide cancer researchers with direct access to minority patient populations. 68 
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The FDA has not followed the NIH's example in requiring the inclusion of minority 
groups in clinical trials. The FDA recommends that these groups be included and makes 
recommendations for how to categorize minority patients. However, the agency does not require 
inclusion of minority groups; instead, individual companies developing and testing new 
interventions decide if and when to include minority groups in their research. 69 
Outside the federal govermnent, several groups have developed programs to increase 
minority participation in research. For example, the National Medical Association supports 
Project IMP ACT: Increasing Minority Participation and Awareness of Clinical Trials. This 
program provides training in research methods to minority physicians and offers educational 
resources for minority patients. The program also collaborates with community organizations 
and other groups to increase awareness of clinical research opportunities. 70 To facilitate 
involvement of minority physicians in clinical research, the program maintains a database of 
minority physicians interested in participating in clinical studies; study sponsors may submit trial 
information to the program to be shared with interested investigators.71 Another example is the 
Center for Innovation in Health Disparities Research, which aims to increase the number of 
minority nurse researchers. The Center provides mentoring and internships to minority 
undergraduate and master's nursing students and provides funding for new research. The Center 
is the result of a partnership between the Department of Nursing at Winston-Salem State 
University and North Carolina Central University and the School of Nursing at The University of 
North Carolina at Chapel Hi11.72 Pharmaceutical companies, such as GlaxoSmithKline and 
AstraZeneca, also sponsor research training and physician engagement programs aimed at 
increasing the participation of minority physicians- and hopefully minority patients- in clinical 
research. 73.74 
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STUDY QUESTIONS AND OBJECTIVES 
In spite ofthe efforts to increase minority participation in clinical research, minority 
groups remain under-represented in CVD research. The goal of this paper is to identify and 
recommend potential strategies for increasing minority patient participation in CVD research. 
The paper describes documented strategies for increasing patient participation in CVD research 
and attempts to examine the relative effectiveness of the strategies. Specifically, this paper 
addresses five questions: What strategies have been documented for increasing the participation 
of minority patients in cardiovascular disease research in the United States? What strategies 
have been documented for increasing the participation of minority patients in research in other 
disease areas or in clinical research generally (e.g., not in a specific disease area)? Are these 
strategies adaptable for cardiovascular disease? Has the effectiveness (and possibly relevant 
effectiveness) of the strategies been assessed? Are there opportunities for collaboration between 
the clinical research and public health sectors to implement new strategies and/or to implement 
existing strategies more efficiently? 
This paper does not address barriers to participation or strategies for increasing 
participation in genomic research into CVD causes or risk factors. Some research has 
documented unique barriers to genomics research, both among majority and minority 
participants. 75 A full review of these unique barriers to genomics research is beyond the scope of 
this paper. 
METHODS 
The primary sources of information for this paper were articles published in peer-
reviewed journals, policy or research papers published by government agencies or non-profit 
associations, and media reports (e.g., newspaper or magazine articles). In January 2010, 
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searches ofPubMed, Google Scholar, and Google were conducted to identity relevant literature. 
PubMed and Google Scholar were used to identify publications in peer-reviewed medical 
literature, while Google was used to identify other publications, such as government policy 
papers, news reports, and magazine articles. The following MeSH term combinations were used 
to search for articles in PubMed: 
• Willingness to Participate AND Minority Groups 
• Patient Participation AND Minority Groups AND Cardiovascular Diseases 
• Patient Participation AND Minority Groups AND Strategy 
• Patient Selection AND Minority Groups AND Cardiovascular Diseases 
• Patient Selection AND Minority Groups AND Strategy 
The phrases, "minority patient participation in clinical research" and "minority patient 
participation in cardiovascular disease research," were used to search for relevant publications on 
Google Scholar and Google. Focused searches of relevant websites, including websites for the 
NIH, Centers for Disease Control and Prevention, American Medical Association, FDA, 
American College of Cardiology, and American Heart Association were also conducted. Lastly, 
the reference lists of included publications were reviewed to identify any additional relevant 
citations. 
Publications that discussed strategies for increasing minority patient participation in 
clinical research (including cardiovascular disease, other disease areas, and clinical research 
generally) in the United States were included. Publications that only discussed clinical research 
participation issues among minority physicians were excluded, as were publications that were 
not available in English, not publically available, or not accessible online in the University of 
North Carolina (UN C) library system. 
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Included publications were organized into two categories: 
1. Strategy Descriptions: descriptive discussions of barriers to minority patient 
participation and strategies for increasing participation, without quantitative 
assessments of strategy effectiveness 
2. Strategy Assessments: quantitative assessments of the effectiveness of various 
strategies to increase patient participation in clinical research 
Publications from the Strategy Descriptions group were used to describe the currently 
available strategies for cardiovascular disease, for other disease areas, and for clinical research 
generally. Publications from the Strategy Assessments groups were used to discuss the 
effectiveness of currently available strategies. Publications from both groups were used to 
describe collaboration approaches. 
LITERATURE REVIEW 
Using the search methods described above, 73 articles were retrieved from PubMed, 
although the number included in the review was less than 73 due to duplicate publications. An 
additional 18 publications were identified through searches of Google Scholar and Google, and 
11 publications were identified by review of article citations. Not all of the identified 
publications were included in the review; publications were excluded primarily because they 
reported low minority recruitment levels for a specific study, without discussions of barriers to 
recruitment or strategies for improving recruitment. The literature review findings are 
summarized below; the findings are organized into strategies specifically designed for CVD, 
general strategies or strategies designed for other disease areas, strategies that discuss 
collaboration across health care sectors, and assessments of strategy effectiveness. 
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STRATEGIES SPECIFICALLY DESIGNED FOR CARDIOVASCULAR DISEASE 
Only two publications described recruitment strategies specifically designed for CVD 
research. First, a 2009 study reported on the use of an ecological systems model to recruit 
minority women at risk for CVD for a study on interventions to increase physical activity. An 
ecological systems model examines individuals' interaction with their environment on four 
levels. The first level is the immediate environment in which the person lives (e.g., family and 
friends). The second level is the broader environment in which the person operates (e.g., 
employment, larger social network). This level is followed by the community in which the 
person resides. The fourth level is the larger society/culture/political group to which the person 
belongs. Each level of the environment has its own roles, culture, behaviors, and norms, which 
in turn influence multiple aspects of the individuals' lives. In this study, the researchers 
attempted to understand how factors at each level might influence patient emollment. The 
researchers assembled a team that included a co-investigator, an African American nurse who 
was familiar with the target population, and two women who were long-time residents in the 
community. The recruitment team identified likely locations for recruitment (e.g., community 
centers) and observed the locations to determine if the target population frequented them. The 
team also observed general community activity over a number of days to determine the most 
promising locations for recruitment activities. Using these techniques, the researchers conducted 
targeted outreach activities and successfully recruited a study population that was over 70 
percent African American. The authors concluded that "culturally competent approaches [to 
recruitment] must include an understanding of the characteristics, experiences, norms, values, 
beliefs, behavioral patterns, social, and environmental forces of the population offocus."76CP669) 
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The second strategy designed for CVD involved a community-wide collaboration. The 
Cherishing Onr Hearts and Souls Coalition (COHS) is a community-based initiative that aims to 
reduce CVD and other chronic health issues among minority groups (particularly African 
Americans) living in Roxbury, Massachusetts. The Roxbury area of Boston has a large minority 
population (less than 15 percent of the residents are white) and significant health issues. The 
Harvard School of Public Health is the coordinating organization for the program; other 
participants include neighborhood health centers, local hospitals, community groups, public 
schools, and local health departments. The group meets several times per year and has several 
active programs related to improving access to care and encouraging healthy behaviors. In 
addition, the program has a specific sub-group that works to improve access to community-based 
research opportunities. The subgroup helped to establish the Roxbury Community Research 
Advisory Board (CRAB), which includes community leaders and residents. The board's goal is 
to improve residents' understanding of and willingness to participate in community-based and 
clinical research; a major function of CRAB is the organization and presentation of training 
sessions that discuss social justice, research ethics and protections, and the ways in which 
increased participation in research may reduce health disparities. COHS has been an important 
partner in minority recruitment efforts for CVD studies in the Boston area.77·78 
STRATEGIES DESIGNED FOR OTHER DISEASE AREAS OR CLINICAL RESEARCH GENERALLY 
Several publications describe strategies for recruitment in disease areas other than CVD 
or for recruitment of minority patients generally. Some of these strategies directly address 
barriers noted above, while others discuss general approaches to recruitment. 
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INCREASE PATIENT KNOWLEDGE 
A study published in 2009 surveyed HIV -infected patients at primary care clinics in 
Chicago to assess reasons for low participation rates in HIV research. The authors found that 
"although less than a third of patients had ever been asked to participate in research, being asked 
by their primary provider was the most important predictor of research participation." 79(P863) The 
authors concluded that busy primary care practices must find new, innovative ways to remind 
physicians about the currently available studies and encourage them to ask patients to participate. 
Strategies for overcoming this barrier may include verbal or electronic reminders about studies 
and the use of other research staff to pre-screen patients and inform physicians about a patient's 
eligibility for trials. 80 
In an example from cancer research, a study examined whether Internet-based tools are 
useful for identifying minority patients that are interested in participating in cancer clinical trials. 
The authors examined data from an Internet-based decision support program designed to provide 
cancer patients with evidence-based information on treatment options for their specific disease. 
Patients using the tool are asked to provide race/ethnicity data early in the questionnaire and are 
later asked if they are interested in learning more about clinical trials. The authors found that 
minority patients were more likely to express interest in clinical trials than white patients. For 
example, 67 percent of white patients indicated interest in clinical trials, while 73 percent of 
African Americans, 74 percent of Hispanics, and 72 percent of Asians indicated interest. The 
authors concluded that Internet -based recruitment tools may be an effective strategy for reaching 
minority patients who are interested in participating in clinical studies. 81 Another cancer study 
disputed this finding, however, suggesting that Internet-based recruitment tools may lead to 
enrollment bias. The authors in this study argue that Internet-based strategies may exclude those 
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oflow socioeconomic status (predominantly minorities) may not have reliable access to the 
Internet. 82 
A systematic review from 2006 attempted to identify major barriers to minority patient 
participation and strategies to overcome these barriers. The authors note that many patients view 
randomized studies that use placebos or double-blind assessments negatively. The authors 
suggest three strategies to address this barrier: education about the advantages of randomization, 
study designs that offer delayed or alternative interventions to the control group, and 
reassurances that control group patients still receive a minimum standard of care.83 
Lastly, in another example from cancer research, a 2007 study used a social ecological 
framework to assess barriers to participation in cancer clinical trials and recommend strategies to 
improve participation. A social ecological framework describes how individuals' interact with 
multiple levels of their environment; the framework is similar to the ecological systems model 
discussed earlier. In this study, the authors used the model to identify barriers to trial 
participation at six levels: intrapersonal, interpersonal, environmental, socio-cultural, 
community, and institutional/societal. The authors suggest that social workers may play a key 
role in connecting patients with research opportunities. Specifically, they suggest placing 
clinical social workers in health care settings where they can be part of the patient's medical 
team; in that role, social workers can help to educate patients about trials and address concerns 
about the process (e.g., informed consent, procedures). 84 
ENGAGE THE COMMUNITY 
Four studies discuss community engagement strategies as a way to increase clinical 
research participation. In an example from HIV research, a 2006 study described a community-
academic partnership for recruiting HIV infected African American and Hispanic women into a 
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research study. In developing the partnership, the authors identified three types of relationships: 
1) researchers ask the community to help them identifY potential participants; 2) the community 
and research team develop a collaborative relationship; and 3) the community initiates the 
research project and asks the academic researchers for support. In their study, the authors 
primarily used the first two approaches. The researchers contacted community organizations 
(e.g., substance abuse centers, counseling centers, clinics), explained the nature of the study, and 
asked for help in recruiting patients. In a few instances, the researchers found opportunities to 
develop a more collaborative relationship with an organization (e.g., finding speakers for lunch 
sessions). Overall, the researchers found that engaging community organizations was an 
effective tool for recruiting patients from a sensitive population. In particular, the authors 
emphasized the importance of establishing personal relationships with supervisors and staff at 
the organization, explaining how the results of the study could benefit their clients, developing a 
plan to help the organization achieve some of its goals, and maintaining a strong presence at the 
organization throughout the life of the study. In terms of actual recruitment efforts, the authors 
emphasize the importance of using culturally matched research staff. 85 A systematic review 
published in 2006 identified similar strategies. The authors of this review recommend the use of 
lay outreach workers, inclusion of minority investigators, and working through community-based 
organizations (e.g., churches) as useful strategies.86 
A report on recruiting Latino patients describes similar recruitment strategies for cancer 
studies. In one example, a cancer screening trial initially had poor enrollment among Latinos. In 
the first five years of the trial, only 232 Latinos had enrolled. The researchers developed a 
campaign to increase participation among Latinos. The campaign included targeted media 
announcements and mailings, community recruiters, and partnerships with other community and 
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medical institutions. During the campaign, 1,046 additional Latinos emolled in the study. In 
another example, the Study of Tamoxifen and Raloxifene (STAR) trial, researchers built 
relationships with professional Latino organizations (e.g., nurses associations, teachers groups) 
to reach their target population of acculturated Latinas. The researchers used these relationships 
to give educational sessions about the study and clinical research generally. 87 
In contrast to these studies, a 2008 report on experiences with recruiting minority women 
into clinical trials related to reproductive health issues found that print marketing was more 
effective than community engagement. The researchers used a combination of print marketing 
materials (e.g., brochures, flyers) placed in high-traffic locations for potential participants and 
outreach to community organizations (e.g., churches, health fairs, public housing units). The 
authors reported successful emollment of African American women in the study, largely in 
response to the print media outreach. They also noted that the community outreach, while useful 
in that it improved ties between the academic medical centers and the community, did not 
substantially contribute to emollment success. 88 
CONSIDER MINORITY PATIENTS IN STUDY DESIGN PHASES 
Two articles discussed study design issues in relation to minority patient participation. 
One study evaluated barriers to cancer clinical trial participation at Howard University Cancer 
Center and found that many African American patients were not eligible due to the presence of 
other co-morbidities (e.g., hypertension, hyperlipidemia). The authors concluded, "It is evident 
that the African American population has a disproportionate burden of co-morbidities that 
exclude patients from clinical trials."89(p?JJ) The authors recommended adjusting inclusion and 
exclusion criteria to allow for the emollment of more African American patients.90 
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The second study used a concept-mapping approach to identify perceived barriers to 
participating in clinical research among minority patients. The authors compared barriers 
identified by community members with barriers perceived by investigators and concluded that 
the actual and perceived barriers are not always the same. The authors recommended that 
researchers include minority patient representatives in the design and implementation of research 
studies as a strategy to overcome actual barriers and increase participation.91 
INCREASE PARTICIPATION AMONG MINORITY PHYSICIANS 
Two publications discussed outreach to minority physicians as a strategy for increasing 
minority patient participation. First, in a report on barriers to minority participation, the authors 
recommended that researchers identify a diverse pool of investigators for studies and use these 
physicians to recruit minority patients. 92 The second publication examined attitudes toward 
clinical research and found that minority physicians and physicians with large numbers of 
minority patients were more likely to express their distrust of medical research and less likely to 
refer patients to clinical trials. This study suggests that efforts to overcome distrust of medical 
research through education about the research process and ethics must include physicians as well 
as patients.93 
STRATEGIES WITH COLLABORATION ACROSS HEALTH CARE SECTORS 
Many health care sectors (e.g., primary care and specialist providers, hospitals, clinics, 
public health departments, academic research centers, pharmaceutical companies and medical 
device manufacturers, non-profit associations, and government agencies) are involved in the 
prevention and treatment ofCVD. An objective of this paper is to identify strategies that involve 
collaboration across these sectors. Three publications described strategies that engaged other 
sectors of the health care community active in CVD treatment and prevention. 
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The first study describes a strategy to recruit minority patients for a trial of a 
telemedicine-based diabetes self-management intervention. The trial was designed and run by an 
academic medical center, but conducted within rural community health centers. The authors 
reported successful enrollment of a representative portion of minority patients using a strategy 
that connected academic researchers with community health care providers. By engaging 
community health care providers, the researchers were able to prospectively identify many 
potential barriers to participation, including distrust of researchers, lack of transportation, and 
time burden. For example, the researchers helped participating heath care providers identify 
eligible patients, but the invitation to the patient came directly from the health care provider. 
This was done to help establish trust in the research study. To avoid transportation issues, the 
study provided free transportation to and from the study site for any necessary study visits. 
Patients also received gift cards and other items (e.g., tote bags, t-shirts) as compensation for 
their time spent participating in the study. The authors concluded that "collaboration between 
the academic institution and the community health center during the planning phase to gain input 
on the development of research practices and continued input by the community health center 
during the Diabetes TeleCare Study facilitated the successful recruitment and retention of an 
ethnically diverse sample, which included a preponderance of females. "94CP69l 
The second study describes a similar strategy for cancer trials. The authors recommend 
that academic research centers and other organizations designing cancer clinical trials engage 
community-based oncology practices to increase participation of minority patients in cancer 
clinical trials. The authors outlined the following steps that community-based practitioners could 
follow to recruit minority patients more effectively: 
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• Encourage open discussion between the patient and physician about participation 
concerns; 
• Clearly address/discuss costs of participating; 
• Include the patient's family in the discussion about participation; 
• Involve the entire staff in recruitment efforts; 
• Hire an ethnically diverse staff with bilingual capabilities; 
• Network with primary care physicians in the community; 
• Develop relationships and network with community organizations/leaders; 
• Build partnerships with local/community-based organizations; 
• Educate the community about research by giving presentations or informal talks; 
• Continue to network with the community after recruitment, and share results from 
research project with the community.95 
The Cherishing Our Hearts and Souls Coalition (COHS) described earlier is a particularly 
relevant example for CVD. This initiative connects local health departments, academic 
researchers, and local providers (clinics and hospitals) to encourage participation in research. 
ASSESSMENTS OF STRATEGY EFFECTIVENESS 
Few publications described systemic assessments of strategy effectiveness, and even 
fewer publications compared the effectiveness of multiple strategies. Only two individual 
studies reported on effectiveness. The first study reported on the effectiveness and cost of 
recruitment strategies for a randomized trial of a smoking cessation program. The authors found 
that active recruitment strategies (e.g., in-person visits by the study staff) were less effective than 
passive strategies (e.g., media outreach and other print dissemination activities). Passive 
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strategies produced 89 percent of the emollees in the study and cost only $22 per emollee, 
whereas active strategies cost $159 per emollee.96 
A second study conducted a formal assessment of the effectiveness of its recruitment 
strategy. This study, which was described earlier, developed a community-academic partnership 
for recruiting HIV infected African American and Hispanic women. The researchers created a 
recruitment success factor (RSF) score and used it to compare recruitment success across 
different organizations. The quantitative aspect ofthe study was helpful in determining which 
types of community organizations were most useful for recruiting patients into an HIV research 
study. However, the effectiveness of the strategy itself(community-academic partnership) was 
not compared to the effectiveness of other strategies (e.g., engaging primary care providers).97 
Two systematic reviews also reported on effectiveness. First, a systematic review 
published in 2006 identified and examined studies that assessed the effectiveness of recruitment 
strategies aimed at increasing minority patient participation in cancer clinical trials. The authors 
identified only five studies that examined the effectiveness of recruitment strategies. The other 
nine studies were descriptive in nature. Of the five studies that assessed effectiveness, three 
reported that the recruitment strategies under study increased minority patient emollment. These 
strategies included media campaigns and a church-based project. The authors conclude that the 
"the small number of studies, their heterogeneity, the lack of consistency in the results, and the 
quality of the evidence suggest that further studies are needed to evaluate the efficacy and/or 
effectiveness of strategies to increase emollment in cancer-related trials."98(Pl39) 
The second systematic review concluded that mass mailings are an effective means of 
recruitment for African Americans, particularly for those of middle or higher socioeconomic 
status. The authors also noted that passive strategies are more effective for studies with large 
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numbers of eligible participants. For studies where eligibility is relatively rare, active strategies 
are more effective. The systematic review did not find sufficient evidence on the effectiveness 
of culturally adapted recruitment materials, and the authors concluded that more study was 
needed. The authors also suggested that more work needs to be done to examine retention 
strategies for minority patients.99 
RESULTS FROM LITERATURE REVIEW 
RESULTS RELATED TO STUDY QUESTIONS 
The goal of the literature review was to identify and recommend potential strategies for 
increasing minority patient participation in CVD research. However, the literature review 
identified few such strategies. Only two documented strategies specifically designed to increase 
participation in CVD research were identified. In both cases, the researchers reported success 
using the strategy, but, since neither strategy was compared to other means of recruitment, no 
objective data exists to support the researchers' views. Without objective data on the 
effectiveness of the strategies, recommending them for use in other studies is difficult. 
Several strategies that were designed for other disease areas or for clinical research generally 
could be adapted for CVD research. For example, strategies to increase patient and physician 
knowledge about clinical research opportunities would be beneficial for CVD research. 
Community engagement strategies may also be useful for CVD research. Study design issues 
may be a barrier in CVD research, but little evidence of this is available in the current literature. 
More research is needed to determine if multiple co-morbidities or other design issues are 
resulting in low eligibility among minority patients for CVD research. 
Limitations to adapting strategies designed for other disease areas to CVD research exist, 
particularly when the diseases are very different in nature from CVD. For example, minority 
Michelle Leavy Master's Paper Page 33 of49 
populations with diseases such as HIV I AIDs may be particularly difficult to recruit due to the 
social stigma surrounding the disease. Researchers must consider this factor when designing 
recruitment strategies for this population.10° CVD, on the other hand, is common in non-
minority groups and occurs across socioeconomic lines; as a result, social stigma is not likely to 
be an issue in recruiting patients for CVD research. The imminently life-threatening nature of 
HIV/AIDS and cancer also may alter patients' willingness to participate in clinical research. For 
CVD, patients may not feel that they are in immediate danger of dying, and therefore may decide 
not to participate. This factor could make it particularly difficult to recruit patients for 
preventive CVD studies. 101 
The available literature describes few collaboration approaches that are specifically 
relevant to CVD. The COHS model noted above is one relevant approach. The strategy of 
building connections between academic research centers and community-based hospitals or 
physicians is also useful for CVD research, since many CVD patients receive care from their 
primary care physician, in their local community. Additional research to develop new 
collaboration approaches and to assess the effectiveness of existing approaches is needed. This 
research may build on the efforts of the cancer community to increase participation in clinical 
trials by linking academic research centers with community-based physicians and with cancer 
advocacy organizations (e.g., the American Cancer Association). 
Lastly, the literature review found very limited evidence on the effectiveness of 
recruitment strategies. The literature primarily described different strategies, without providing 
any quantitative analysis of the strategy effectiveness. 102 The available assessments generally 
report only on effectiveness of a single strategy for a specific study. Few assessments compare 
multiple approaches to recruitment for a single study, and even fewer studies compare 
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recruitment strategies across minority populations (e.g., African American vs. Hispanic). More 
research is needed in this area to understand the effectiveness of various strategies, both 
generally and in specific sub-populations. The conclusions of one systematic review hold true 
for CVD as well as cancer. The authors of that review recommended that "researchers design 
and evaluate the efficacy and/or effectiveness of recruitment strategies tailored to specific under-
represented groups."103(P140) 
GAPS IN EXISTING LITERATURE 
Overall, the literature review revealed a startling lack of evidence on which recruitment 
strategies would be effective for increasing minority patient participation in CVD research. In 
addition, the review identified several other major gaps in research and strategy development in 
this area. Specifically, the review found little to no information on how the nature of the 
organization conducting the research affects patient trust and participation, on what motivates 
researchers to recruit minority populations, and on how the problem could be addressed from a 
broader, public health leadership perspective. 
ORGANIZATION TYPE AND PATIENT TRUST 
Clinical research in the United States is generally conducted by one of three groups: 
government, academia, and industry. Each group has different motivations for conducting 
research. Patients who are approached about participating in a study receive information on the 
study sponsor. The study sponsor may influence the patients' willingness to participate in the 
study. For example, patients may be more distrustful of research sponsored by pharmaceutical 
companies, for fear that the sponsor is motivated by financial concerns and not concerns about 
the patients' health. Alternately, minority patients may be more distrustful of government-
sponsored studies, given the history of the Tuskegee syphilis study. None of the identified 
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literature explored whether the type of organization sponsoring the research influenced patient 
participation. More research is needed in this area to identify if this is a barrier to research and, 
if so, to develop appropriate strategies to overcome this obstacle. 
MOTIVATIONS FOR RESEARCHERS TO RECRUIT MINORITY PATIENTS 
Another critical issue that was not addressed in the literature review is how to motivate 
researchers to include minority patients in their studies. Most publications discussed the broad 
reasons, such as reducing health care disparities and providing equal access to research benefits, 
for including minority patients in their studies. However, the authors did not address how to 
motivate researchers to make a substantial effort to improve participation rates. This is a 
significant issue. The NIH mandates enrollment goals and plans for recruiting minority patients, 
but studies may still be unsuccessful in meeting their goals. The FDA does not require inclusion 
of minority groups in clinical research. The literature review shows that recruitment of 
representative minority populations generally requires substantial effort, time, and money. 
Because of the lack of mandate, researchers may make a good faith effort to enroll minority 
patients, but they may limit their activities to avoid going over budget or missing enrollment 
deadlines. Researchers may understand the importance of including minority populations, but 
may not do so in practice due to the logistical difficulties. More research is needed to understand 
why some researchers make a substantial effort to include minority patients, and why other 
studies fail to do so. Research is also needed to better understand what would motivate 
researchers to make a stronger effort to recruit minority patients. 
PUBLIC HEALTH LEADERSHIP PERSPECTIVE 
A surprising finding of the literature review was the lack of high-level strategies for 
addressing the issue of minority participation rates. Almost all of the literature identified here 
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focused on strategies for specific types of studies, in specific disease areas. The strategies 
described in these publications are intended for individual research teams. Only one of the 
reviewed publications, from the Endocrine Society, discussed the issue from the perspective of 
the public health leadership framework. The public health leadership framework includes 
competencies related to effective change, political processes, negotiation and mediation, ethics, 
organizational capacity, and team building. The authors of this publication assessed the issue 
from several perspectives and identified the need for transformational change. The authors then 
examined trans-organizational capacity and identified the major stakeholders for this issue, 
including the NIH, FDA, pharmaceutical companies, academic institutions, health care 
providers, community organizations, and patient groups. Next, the authors recommended a 
team-building approach and suggested creating collaborative centers between the NIH, 
researchers, and other stakeholders. These centers would develop and test recruitment strategies 
and assist with recruitment efforts. From a political standpoint, the authors recommended 
passing new federal laws to require research to include minority patients, providing tax breaks or 
other incentives to offset increased costs of recruitment, and requiring minority participation in 
trials for FDA approval. 104 
While the strategies put forth in this paper are interesting and potentially useful for 
addressing the issue of minority patient participation, further analysis of the problem from a 
public health leadership standpoint is needed. Given the scope of the problem and the lack of 
success in improving participation rates to date, solutions that tackle the issue from a systems 
level are needed. 
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CONCLUSIONS AND RECOMMENDATIONS 
The health care community generally agrees that clinical research should be more 
representative of minority populations in the United States. Many barriers to minority patient 
participation have been identified, and some strategies have been suggested to improve 
participation. However, few strategies have been designed specifically for CVD research, and 
more research is needed to determine whether strategies documented for CVD and those 
documented for other disease areas are effective in CVD. As noted above, costs vary 
dramatically between strategy types. In order to make the best use of limited research resources, 
it will be important to understand what strategies are most effective and most cost-efficient. This 
may vary by study type (interventional vs. observational), by the area of study (treatment vs. 
prevention), by the geographic location of the study (rural vs. urban), and by the characteristics 
of the target population (elderly vs. young, African American vs. Hispanic, men vs. women). 
The lack of documented, effective strategies for increasing participation in CVD research 
clearly points to a need for new research to develop and test strategies. Researchers undertaking 
new studies may find it useful to undertake a small feasibility study to assess barriers to 
recruitment and strategies to overcome those barriers. The feasibility study could include 
surveys or other interviews with potential participants. This will allow the researchers to design 
the study in a manner that avoids some of the key barriers for that population. For example, 
researchers may learn that transportation, and not language or cultural issues, are the key barrier 
for a particular group. Rather than spending the recruitment budget on translating materials and 
hiring culturally appropriate staff, the researchers may arrange for alternate locations or pay for 
transportation services. Prospective identification of barriers will be a critical factor in 
developing a cost-effective approach to engaging minority populations. 
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Secondly, new analyses of the problem from the public health leadership standpoint are 
critical for the development of systems level strategies to address this issue. The currently 
documented strategies are intended for addressing barriers at the individual study level. 
However, broader strategies are needed to address systems level issues, such as the lack of 
motivation for researchers to recruit minorities for clinical research studies. The use of political 
processes, including new laws and requirements for FDA approval, may be particularly useful 
for addressing the motivation issue. Team-building approaches may help to improve knowledge 
sharing and reduce the logistical difficulties around recruiting minority patients. 
Transformational change to existing organizations and systems may be necessary to increase the 
number of minority physicians and to eliminate the barriers of insurance coverage and access to 
care. Most importantly, perhaps, the public health community needs to develop and articulate a 
clear mission to address this issue, across disease areas. 
A potential barrier to successful public health leadership on this issue is the lack of a 
clear primary stakeholder. No organization is currently empowered with this mission, and so it 
becomes a lower-tier priority at many groups, such as the NIH and FDA. A potential solution is 
to empower an agency (with funding and authority), such as the Office of Minority Health at the 
Department of Health and Human Services, to take charge of addressing this issue. 
Placing this issue in the charge of a single agency may help to promote collaboration 
between health care sectors. This paper identified few examples of strategies that attempted to 
bridge the gap between academic or industry-funded research and public health organizations. 
As part of the Healthy People 2010 initiative, public health organizations across the country are 
working to reduce health care disparities and improve prevention and treatment for major disease 
areas, including CVD. Many public health organizations have campaigns to raise awareness or 
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to prevent the disease by reducing risk factors. Others attempt to provide higher quality care for 
patients with acute CVD. As an example, the American Heart Association organizes campaigns 
to raise awareness of CVD and to reduce risk factors, such as smoking, obesity, high blood 
pressure, and high cholesterol. The organization also works with hospitals to improve the quality 
of care for patients with the disease. Many of these programs are conducted in partnership with 
public health agencies, at the local, state, and federal levels. 
Despite the high level of activity related to CVD in public health organizations, few 
documented attempts to connect public health activities to clinical research exist. Public health 
organizations may be reluctant to promote specific studies in CVD, either due to lack of 
resources or to the perception of a conflict of interest. For example, it would likely be 
inappropriate for the Centers for Disease Control and Prevention to specifically support 
recruitment activities for a clinical trial of a new antihypertensive. However, the above 
discussion of barriers and strategies points to several areas where public health organizations 
could contribute to improving minority participation inresearch. Collaboration on education 
would be particularly useful; for example, as part of efforts to increase awareness of CVD and 
risk factors, public health agencies could add a component on clinical research to their education 
programs. This component could focus on research generally; it could explain the importance of 
research participation, the concept of randomization, the benefits and potential risks of 
participating in research, and the informed consent process. Educating minority groups about 
clinical research generally would help potential study participants to make a more informed 
decision about emolling in a clinical study. 
In conclusion, this literature review identified few strategies specifically designed to 
increase minority participation in CVD research. Other existing strategies may be adapted for 
Michelle Leavy Master's Paper Page 40 of49 
CVD research, but assessments of the effectiveness of these strategies are necessary before they 
are widely implemented. New research should be conducted to develop and test effective 
strategies for CVD research. New strategies and approaches to addressing this issue are needed, 
both at the individual study level and at the broader systems level. Addressing the issue from a 
public health leadership standpoint may be particularly useful for developing new, systems level 
strategies. Researchers should also investigate the potential for partnerships with public health 
organizations that are already investing in education, prevention, and treatment campaigns for 
CVD. Increasing minority participation in CVD research is a critical step in reducing the burden 
of CVD among minority populations and eliminating health care disparities in the United States. 
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